SCHOTT Pharma's Strong Outlook
SCHOTT Pharma Q3 2026 Revenue Growth Drives Up Full-Year Guidance on Strong Demand
Key Points
In Q3 2026, SCHOTT Pharma reported quarterly sales of EUR 281.76 million (up from EUR 256.18 million a year earlier) and Q3 net income of EUR 38.83 million with diluted EPS of EUR 0.26; nine-month sales reached EUR 769.83 million and nine-month net income EUR 103.02 million (EPS EUR 0.68).
The company flagged a one-off Q4 revenue item that contributed to the upgraded full-year guidance.
For the first nine months of 2026, EBITDA margin was 26.7%, down from 28.9% a year earlier, with declines driven by inventory impairments and higher DDS costs.
Revenue guidance was raised supported by a key customer agreement, contributing to the FY2026 outlook for 5-6% revenue growth at constant currencies and an EBITDA margin of 27-28%.
Market reaction noted SCHOTT Pharma’s stock trading around EUR 22.42 on XETRA following the results release.
SCHOTT Pharma posted strong third-quarter results, lifting its full-year guidance after syringe demand recovered and high-value solutions kept growing. Quarterly sales rose to EUR 281.76 million, up from EUR 256.18 million a year earlier — a gain of about 8.3% at constant currencies, according to Quartr.
The German pharma packaging maker now expects full-year revenue growth of 5-6% at constant exchange rates, up from a prior forecast of 2-5%, and an EBITDA margin of 27-28%. Investing.com reported the upgrade was driven by recovering syringe demand and a key customer agreement with a one-off revenue item in Q4.
High-Value Solutions Carry More Than Half of Sales
SCHOTT Pharma's so-called high-value solutions — its premium, more complex packaging products — now make up 59% of total sales. That share has kept climbing. TradingView noted this segment is a key engine behind the company's stronger pricing power and overall revenue mix.
For the full nine months ending June 30, 2026, sales reached EUR 769.83 million. Net income for that period came in at EUR 103.02 million, or EUR 0.68 per diluted share. Q3 alone produced net income of EUR 38.83 million, or EUR 0.26 per share, according to MarketScreener.
EBITDA Margin Squeezed by Impairments and DDS Costs
Profitability came under some pressure. The nine-month EBITDA margin fell to 26.7%, down from 28.9% a year earlier. TradingView said inventory impairments and higher costs tied to the company's drug delivery systems — or DDS — business were the main culprits.
EBITDA for Q3 stood at around EUR 75 million, and EUR 205 million across the first nine months. Despite the margin dip, management expects to recover ground in Q4. The raised full-year EBITDA margin target of 27-28% implies a meaningful step-up in the final quarter.
Free Cash Flow Surges 49% on Working Capital Gains
Free cash flow jumped roughly 49% to EUR 141 million over the nine-month period. Quartr attributed the gain to working capital improvements and lower tax payments — two factors that helped offset the softer earnings margins.
Capital expenditure for the full year is expected to land between EUR 140 million and EUR 160 million. The company is expanding capacity in the U.S., Hungary, and Switzerland. Management also appointed a new Chief Commercial Officer to strengthen customer relationships and future demand, according to TradingView.
Stock Ticks Up as Market Digests Upgraded Outlook
Investors reacted calmly to the results. SCHOTT Pharma shares traded at around EUR 22.42 on XETRA following the release. The guidance upgrade — anchored by a specific customer deal and a one-off Q4 revenue item — gave analysts a clearer picture of where full-year numbers will land, MarketScreener noted.
The company's high-value solutions share is expected to stay near current levels for the rest of the fiscal year. With syringe demand recovering and strategic capacity coming online, SCHOTT Pharma is positioning itself for steadier growth heading into fiscal 2027.
Sentiment
Mostly NegativePublishers
11
Articles
24
Reach
35
